BioNTech (NASDAQ:BNTX) SE (NASDAQ: BNTX) is a global biotechnology company headquartered in Mainz, Germany, that develops and manufactures active immunotherapies for a range of diseases. Using its proprietary messenger RNA (mRNA) technology platform, BioNTech designs novel treatments that harness the body’s immune system to target cancer, infectious diseases and other serious medical conditions. The company’s research and development efforts span oncology, rare diseases and vaccines, with an emphasis on personalized approaches.
Central to BioNTech’s business is its mRNA-based pipeline, which includes individualized cancer vaccine candidates tailored to a patient’s tumor profile, as well as off-the-shelf modalities for solid tumors and hematological malignancies. Beyond oncology, BioNTech has advanced infectious disease vaccines, most notably its collaboration with Pfizer to co-develop a COVID-19 vaccine. The success of this partnership has reinforced the company’s platform validity and expanded its manufacturing footprint in Europe and North America.
Founded in 2008 by husband-and-wife team Dr. Ugur Sahin and Dr. Özlem Türeci, BioNTech has grown from a small startup into a publicly traded entity following its initial public offering on the Nasdaq in 2019. The company’s leadership team combines academic expertise and industry experience, with Dr. Sahin serving as Chief Executive Officer. BioNTech maintains research sites in Germany and the United States and collaborates with global academic institutions, biopharmaceutical partners and public health organizations to accelerate the development and distribution of its products.
BioNTech’s operations extend across Europe, North America and select international markets, supported by strategic partnerships that facilitate clinical trials, regulatory approvals and large-scale manufacturing. The company continues to advance its mRNA platform into new therapeutic areas, pursuing collaborations and in-licensing opportunities to broaden its pipeline and address emerging medical needs worldwide.
